OTC · HSTC
HST Global, Inc.
$0.70$0.00 (0.0%)
HST Global, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
Loading market information…
OTC · EVLO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Evelo Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Evelo Biosciences, Inc.’s next earnings report is currently expected on Nov 17, 2026, with estimated earnings per share of -$10.13. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Evelo Biosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:10 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 |
|---|
| May 12, 2022 |
| -$11.14-1,820.69% vs estimate |
| $0.00 |
| Q4 2021 | Mar 24, 2022 | -$0.54+11.48% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.70$0.00 (0.0%)
HST Global, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.33% below the high.
$0.00+$0.00 (0.0%)
PaxMedica, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 96.5% below the high.
$0.00$0.00 (0.0%)
Life Stem Genetics Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
$0.00$0.00 (0.0%)
Biostax Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.01$0.00 (0.0%)
Trevena, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.26% below the high.
$0.00$0.00 (0.0%)
Infinity Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.15% below the high.
$0.00$0.00 (0.0%)
Aridis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00$0.00 (0.0%)
Statera Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.62% below the high.
